NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Eureka Bio

Eureka Bio

Private
ShenzhenHealthcare & Life Scienceshttps://www.eurekabio.com/

Last Round

Series B

Feb 21, 2024

Total Funding Raised

$54.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Eureka Bio is a biotechnology company that provides automated cell processing systems and viral vector manufacturing platforms for the cell and gene therapy (CGT) industry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Smart Manufacturing, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

cell and gene therapyCGTviral vector manufacturingbioprocessingautomated cell processinglentiviral vectorproducer cell linebiotech automationlab automationGMP manufacturingbiotech equipmentclone screeningbioprocess engineeringbiotech R&Dbiopharma tools

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eureka Bio Comparables

Compare Eureka Bio with similar companies based on industry and business-model similarity.

Eureka Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ori Biotech
80%
Scinogy
77%
Vector Process Innovation
76%

Eureka Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 21, 2024
Series BJun 21, 2022
Series AApr 23, 2021
Pre SeedOct 1, 2020
AngelDec 1, 2018

Eureka Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors grew 382% MoM, reaching 1.1K.

  • Feb 18, 2025

    Collaborates with VectorBuilder Inc. to lower viral vector production costs.

Eureka Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eureka Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eureka Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen
Employee Range13
Year Founded2014
Last FundingFeb 21, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.